Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Update

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 4,900 shares, a decrease of 53.3% from the August 15th total of 10,500 shares. Based on an average trading volume of 37,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.4% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, Maxim Group upgraded Synaptogenix from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Thursday, July 11th.

Synaptogenix Stock Up 10.9 %

SNPX stock traded up $0.31 during trading hours on Friday, hitting $3.16. 28,785 shares of the stock were exchanged, compared to its average volume of 38,357. The company has a 50-day simple moving average of $3.84 and a two-hundred day simple moving average of $4.32. Synaptogenix has a 12 month low of $2.72 and a 12 month high of $11.47.

Synaptogenix (NASDAQ:SNPX) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($1.18) earnings per share for the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.